http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CY-1110188-T1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eedb53b18972fa06716e56945d4388ed |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-323 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39583 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44 |
| filingDate | 2010-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd2a591c74f4129d1a06b7ef4ce4f602 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d86dda3493b00bf6e8055eb8a289451 |
| publicationDate | 2015-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CY-1110188-T1 |
| titleOfInvention | ANTIBODIES AGAINST PHOSPHYLCHOLINE SPOINES |
| abstract | Levels of IgG and IgM autoantibodies against phosphorylcholine in hypertensive subjects (diastolic pressure> 95 mmHg) at baseline were determined to determine the importance of antibodies for the development of atherosclerosis. The results indicate that the increase in IMT at four years post-baseline was significantly less pronounced in subjects with high autoantibodies, particularly IgM autoantibodies, to phosphorylcholine. Therefore the presence or absence of autoantibodies, particularly IgM autoantibodies, to phosphorylcholine is associated with an increased or decreased risk of developing cardiovascular disease. The present invention proposes a method for the determination of antibodies, particularly phosphorylcholine IgM antibodies, for the identification of individuals at risk for developing ischemic cardiovascular disease. Animal experiments indicate that moderate to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a hemocyanin (KLH) -phosphorylcholine conjugate. A pharmaceutical composition comprising a phosphorylcholine conjugate (active immunization) or an antibody preparation, for example a monoclonal antibody, selectively to a phosphorylcholine conjugate (passive immunization) and the use of these compositions as active or passive immunoassays atherosclerosis. |
| priorityDate | 2004-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483782 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1014 |
Total number of triples: 32.